Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients
about
Inhaled anticholinergics and short-acting beta 2 -agonists versus short-acting beta2-agonists alone for children with acute asthma in hospitalRegular treatment with formoterol for chronic asthma: serious adverse eventsAddition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with formoterol for chronic asthma: serious adverse eventsAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaChronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha)Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonistsSystemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacerInteractions between corticosteroids and beta agonists.β-Agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent.The pharmacogenetics of asthma: a candidate gene approach.Antagonism of long-acting beta2-adrenoceptor agonism.Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo.Management of asthma in adults: current therapy and future directionsCombination therapy: appropriate for everyone?Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterolAdverse effects of beta-agonists: are they clinically relevant?Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trialsComparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutalineThe use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysisChronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.Assessment of murine lung mechanics outcome measures: alignment with those made in asthmatics.Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma.Beta2-agonist tolerance and exercise-induced bronchospasm.Rosiglitazone elicits in vitro relaxation in airways and precision cut lung slices from a mouse model of chronic allergic airways disease.A CREB-mediated increase in miRNA let-7f during prolonged β-agonist exposure: a novel mechanism of β2-adrenergic receptor down-regulation in airway smooth muscle.
P2860
Q24194751-576C1E9B-7EC3-47A1-A9AA-0FBC01E043D5Q24200353-34155746-0FC8-42AA-AF69-CC28920AE757Q24235303-E628CFB6-BC6F-426D-AD00-58DE82C27C67Q24235964-BAA3734A-555C-4AF9-9B04-300D526DF343Q24240464-63B77749-C57B-4536-925B-299F05A54693Q24241250-19E93864-136C-4C9E-AFDC-B12BA6E74E89Q24245719-CB4FF7FD-343F-4C48-9274-2001198A3A30Q24246441-D2955B57-0D8E-4ED3-B13E-731DBD762BF2Q24247926-E5732E43-9FA3-4B8C-99A7-B4B253E6D803Q28360183-45BD19DB-43A1-4056-8013-CB88181ECBD8Q28367141-3394A4FF-501F-4E7D-AFA0-99D5D1046155Q33906322-0E5139DC-5432-4387-AD0D-772FB989C9C2Q33944522-FFAAB286-1145-4226-8525-6B51A05FEEADQ34044729-D62B3DD6-698A-40A6-AEF8-A8917EEF01EAQ34576923-C3C75593-4149-4FF9-80D5-6B285A13FD56Q34866359-633A09E2-DABE-47AE-9B23-B0812196A648Q35127998-DF21364C-9A39-46A0-B0EA-F106C4490288Q35143482-A1AE858E-62F7-4D21-BEF2-B230AD478011Q35180953-3D02C21F-049C-4420-841C-778171285A94Q35532986-73D014F5-C4AE-4937-8C1C-84BA73DF74EBQ35536841-9EA04ED5-51C2-4FB7-991B-E62918355205Q35627643-159B271B-3314-4057-90D6-C5D30F10F938Q35677555-79584419-8C2C-4A65-B1AD-19BEEE41577DQ35825799-D46DA349-0917-4A2B-9135-400FB327E99EQ35826418-608892AF-945A-4147-BBE8-89AA90BE6348Q35939347-B1750071-6417-482D-938C-2FF2DC53A735Q36147356-70C66627-9D28-4151-89EC-2BD81F293C29Q36602201-6B081682-12E8-429C-8228-5A5B90F77BD2Q37589707-DA6188E3-880F-4246-8D5C-0F0E2191B05AQ37822833-6B659BF5-2128-4527-B72E-BC9B7CAE1AE1Q38700260-297B6AFA-8CF3-44CB-92F4-CA620C20F91CQ43961067-B2A1C537-8FDD-489F-91AB-4CB417C87465Q46858495-E6EFFE95-4BE0-44C8-BD04-CA6EF9B81480Q49888779-402AE1AD-4B74-4DA1-91E7-D2FB4DB9BEC6
P2860
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@ast
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@en
type
label
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@ast
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@en
prefLabel
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@ast
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@en
P2093
P2860
P356
P1433
P1476
Subsensitivity of bronchodilat ...... y powder in asthmatic patients
@en
P2093
B J Lipworth
D G McDevitt
D M Newnham
P2860
P304
P356
10.1136/THX.50.5.497
P407
P577
1995-05-01T00:00:00Z